Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
China
Hangzhou First People's Hospital, Hangzhou Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai